William D. Tap

Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).

Katherine Thornton, David A. Liebner, Robin L. Jones, 2017 .

Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas

Michael E. Phelps, Robert M. Elashoff, Scott D. Nelson, 2008, Clinical Cancer Research.

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Gary K. Schwartz, Douglas R. Adkins, C. Antonescu, 2015, Cancer Chemotherapy and Pharmacology.